5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Europe Nuclear Medicine Market is segmented by Product Type (Diagnostics and Therapeutics), Application, and Geography
The Europe Nuclear Medicine Market is growing due to the rising prevalence of cancer and cardiac disorders and the increasing demand for image guided procedures and diagnostics.
Nuclear medicine has shown a huge potential in treating cardiac and cancer diseases. According to WHO, it is estimated that 3.7 million new cases and 1.9 million deaths occur every year due to cancer, and cancer disease represents the second most significant cause of death and morbidity in Europe. Therefore the cardiology applications will also continue to demonstrate strong growth in the market. There are also other factors, such as increasing SPECT and PET applications and growing public awareness for healthcare that are also expected to drive the market in the future.
Regulatory requirements pose another hurdle to translational research and clinical investigations. In Europe, all the guidelines for nuclear medicine products are coordinated by the European Association of Nuclear Medicine (EANM) and, including diagnostic radiopharmaceuticals and radio therapeutics, undergo regulatory procedures by European Medicines Agency (EMEA). Radiopharmaceuticals therefore undergoes unique regulatory and approval pathways. Sometimes, extensive toxicology testing poses considerable financial burdens for the investigators.
As per the scope of the report, nuclear medicine falls under the field of molecular imaging, which involves the use of a very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by special types of cameras attached to the computer, which in turn, provide very precise pictures of the area of the body examined.
|Single Photon Emission Computed Tomography (SPECT)|
|Positron Emission Tomography (PET)|
Report scope can be customized per your requirements. Click here.
The nuclear imaging is used in the diagnosis and treatment of various diseases such as heart disease, cancer, and brain disorders by taking a small amount of radioactive particle and then determining the response with external detectors such as gamma cameras. These devices help in determining the severity and progression of the disease so that effective medication program can be developed. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died, due to CVDs. Therefore with the increasing cardiology diseases the segment is expected to have a positive contribution in the market growth.
To understand key trends, Download Sample Report
There is high competition among the players of the global nuclear medicine market. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. The major players in the Europe nuclear medicine market include Advanced Accelerator Applications, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Isotec Inc. (Sigma-Aldrich), Mallinckrodt Pharmaceuticals, Nordion Inc., and Siemens AG.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidents of Cancer and Cardiac Ailments
4.2.2 Increasing SPECT and PET Applications
4.3 Market Restraints
4.3.1 Strict Regulatory Guidelines
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Diagnostics
5.1.1 Single Photon Emission Computed Tomography (SPECT)
5.1.2 Positron Emission Tomography (PET)
5.2 By Therapeutics
5.2.1 Alpha Emitters
5.2.2 Beta Emitters
5.3 By Application
5.3.4 Other Applications
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Advanced Accelerator Applications
6.1.2 Bracco Imaging SpA
6.1.3 Cardinal Health Inc.
6.1.4 Curium Pharma
6.1.5 GE Healthcare
6.1.6 Isotec Inc. (Sigma-Aldrich)
6.1.7 Nordion Inc.
6.1.8 Siemens Healthineers AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments